

# Nuvalent to Participate in the Cowen 42nd Annual Healthcare Conference

CAMBRIDGE, Mass., March 2, 2022 /PRNewswire/ -- [Nuvalent, Inc.](#) (Nasdaq: NUVL), a biopharmaceutical company focused on creating *precisely* targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will participate in a virtual panel titled, "Lung Cancer Panel," during the Cowen 42<sup>nd</sup> Annual Healthcare Conference on Wednesday, March 9, 2022, at 9:10 a.m. ET.

A live webcast will be available in the investor section of the company's website at [www.nuvalent.com](http://www.nuvalent.com), and archived for 30 days following the presentation.

## **About Nuvalent**

Nuvalent, Inc. (Nasdaq: NUVL) is a biopharmaceutical company focused on creating *precisely* targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), along with multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at [www.nuvalent.com](http://www.nuvalent.com). Follow us on Twitter ([@nuvalent](#)) and [LinkedIn](#).

SOURCE Nuvalent, Inc.

## **Investor Contact:**

Chelcie Lister  
THRUST Strategic Communications  
[chelcie@thrustsc.com](mailto:chelcie@thrustsc.com)

## **Media Contact:**

Amanda Sellers  
Verge Scientific Communications  
[asellers@vergescientific.com](mailto:asellers@vergescientific.com)

---

<https://investors.nuvalent.com/2022-03-02-Nuvalent-to-Participate-in-the-Cowen-42nd-Annual-Healthcare-Conference>